Adcoris is a clinical stage biopharmaceutical company focusing on developing the new generation antibody drug conjugate (ADC) and antibody conjugate beyond cytotoxic payload (AXC) therapeutics to meet the unmet needs in oncology and autoimmune disease. Adcoris’ cutting edge ADC platform consists of three pillars: proprietary and highly active payloads (PHAP™), cleavable, flexible and stable linkers (CLEFS™), multifunctional site-specific conjugation (MuSC™). We can accelerate the development of ADC products from target to IND-enabling within 15 months. We have a robust pipeline including first-in-class (FIC) and first-in-generation (FIG) ADC in various development stage.